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Abstract Tissue-factor pathway inhibitor (TFPI) inhibits the 
procoagulant activity of the tissue-factor/factor Vila complex. It 
was recently reported that TFPI prevented restenosis following 
tissue injury in a rabbit atherosclerotic model. In order to clarify 
the mechanism behind this successful prevention of restenosis, we 
investigated the direct effect of human recombinant TFPI (h-
rTFPI) on the proliferation of cultured human neonatal aortic 
smooth muscle cells (hSMC). We found that h-rTFPI exhibits 
inhibitory activity toward hSMC proliferation, while h-rTFPI-C 
which lacks the carboxyl (C)-terminal region does not. 
Furthermore, we found that h-rTFPI binds to hSMCs with 
Ä"d = 526 nM but that this binding is inhibited by the addition of 
the synthetic C-terminal peptide, Lys254-Met276, to h-rTFPI. 
Thus, the interaction of h-rTFPI with hSMCs mediated via the 
C-terminal region is responsible for the anti-proliferative action 
of h-rTFPI. On the basis of these results, we presume that the 
anti-proliferative effect of h-rTFPI in addition to its anti-
coagulant function plays a significant role in preventing reste-
nosis following tissue injury. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The proliferation of aortic smooth muscle cells (SMC) is a 
key event in the development of arterial lesions such as neo-
intimal hyperplasia after vascular injury and atherogenesis [1-
3]. Various types of growth factors which are secreted from 
platelets, macrophages, and vascular cells have been identi-
fied, and the involvement of these growth factors in the devel-
opment of arterial lesions has been suspected [4]. However, 
the identification of growth inhibitors has received little atten-
tion, which has instead been focused on the characterization 
of growth promoters of SMCs. Among the inhibitors so far 
reported [5], heparin/heparan sulfate is well characterized and 
has been used for clinical intervention to prevent restenosis 
after balloon angioplasty [6,7]. Jang et al. [8] recently demon-
strated that treatment with tissue-factor pathway inhibitor 
(TFPI) in a rabbit atherosclerotic model reduces angiographie 
restenosis. 
TFPI is a Kunitz-type protease inhibitor which exhibits a 
strong and specific inhibitory activity against tissue factor 
(TF)-mediated initiation of the blood coagulation cascade 
[9,10]. TF expressed on cellular surface binds to factor 
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VI 1(a) and activates factors X and factor IX, leading to the 
triggering of the extrinsic coagulation cascade [11]. It has been 
reported that TF is highly expressed in human atherosclerotic 
plaque and in rat aortic medial SMCs following balloon in-
jury [12,13]. Therefore, the inhibitory activity of TFPI may 
contribute to the inhibition of the extrinsic coagulation path-
way triggered by TF in the lesions. However, we cannot rule 
out two possible mechanisms by which TFPI prevent resteno-
sis: (1) the anti-proliferative effect of TFPI on SMCs, and (2) 
the inhibitory activity of TFPI toward the migration of SMCs 
from the media to the intima. In order to clarify the specific 
mechanism of the prevention of restenosis by TFPI, we at-
tempted to investigate the direct effect of human recombinant 
TFPI (h-rTFPI) on the proliferation of cultured human aortic 
SMCs (hSMC). SMCs in the restenosed lesions have been 
shown to be 'synthetic' SMCs with high proliferative poten-
tial, and have characteristics similar to neonatal SMCs iso-
lated from the neonates [14]. In the present study, we used 
neonatal hSMCs instead of SMCs in the restenosed lesions 
because we could not obtain SMCs from the restenosed le-
sions. We found that h-rTFPI inhibits hSMC proliferation 
and that the anti-proliferative effect of h-rTFPI is mediated 
by the binding of its carboxyl (C)-terminal region with 
hSMCs. 
2. Materials and methods 
2.1. Materials 
h-rTFPI was isolated from the culture medium of transformed Chi-
nese hamster ovary cells by immunoaffinity chromatography using its 
monoclonal antibody (HTFPIK-9)-conjugated Cellulofine (Seikagaku 
Co., Tokyo, Japan), as previously described [15]. For the separation 
of h-rTFPI from h-rTFPI-C, which lacks the C-terminal region, we 
performed an affinity chromatography on a heparin-Sepharose CL-6B 
(Pharmacia-LKB Biotechnology, Uppsala, Sweden) column (2.7X8.8 
cm). A chemical analysis of the isolated materials showed that h-
rTFPI was a full-length form [16], whereas h-rTFPI-C ended at 
Lys249 [17]. The h-rTFPI concentration was determined by measuring 
the inhibition of factor Xa activity after incubation of factor Xa with 
serially diluted h-rTFPI as previously described [18], The HTFPIK-9 
monoclonal antibody was prepared by the methods described in a 
previous paper[19]. For the ELISA, the specific polyclonal antibody 
against h-rTFPI was prepared by injecting h-rTFPI into the guinea 
pigs. 
The following peptides (CTP) were purchased from Sawady Bio-
technology Co. (Tokyo, Japan): CTP23, KTKRKRKKQRVKIAYE-
EIFVKNM (Lys254-Met276); CTP11, KTKRKRKKQRV (Lys254-
Val264); CTP12, KIAYEEIFVKNM (Lys265-Met276). The concentra-
tions of these peptides were determined by amino acid analysis. 
The following materials were obtained from the listed companies: 
unfractionated heparin (180 U/mg, Shimizu Pharma., Shizuoka, Ja-
pan), crystallized bovine serum albumin (BSA; Sigma Chemical Co., 
St. Louis, MO), peroxidase-conjugated rabbit anti-guinea pig anti-
body (Dako Japan, Kyoto), Block Ace (Dainihon Pharma., Osaka, 
Japan), benzamidine (Tokyo Kasei, Japan). All other chemicals, re-
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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agent grade or better, were from Wako Pure Chemical Industries 
(Osaka, Japan) or Nacalai Tesque (Kyoto, Japan). 
2.2. hSMCs culture 
Neonatal hSMCs were purchased from Kurabo Co. (Osaka, Ja-
pan). The cells were isolated from an aortic media in neonate, and 
identified by an immunological analysis of a-actin (positive) and von 
Willebrand factor (negative). hSMCs were cultured in growth me-
dium, Humedia-SG2 (Kurabo Co.), and were grown at 37°C in a 
humidified atmosphere at 5% of CO2 in air. Humedia-SG2 medium 
contained 5% fetal bovine serum (FBS), 0.5 ng/ml recombinant epi-
dermal growth factor (rEGF), 2 ng/ml recombinant basic fibroblast 
growth factor (r-bFGF), and 5 ng/ml insulin. We changed the medium 
every 2 days. For growth rate determination, cells were detached by 
treatment with 0.025% trypsin containing 0.01% EDTA (Kurabo Co.) 
and counted in a Coulter counter (Japan Scientific Instruments Co., 
Osaka). Cells were routinely used from the fifth to sixth passage. 
2.3. Binding assays of h-rTFPI to hSMCs 
The cells were seeded at 2500 cells/cm2 in a 96-well plate (Becton 
Dickinson, New Jersey) and cultured in growth medium. The culture 
medium was changed every 2 days, and a confluent monolayer was 
obtained after 6 days. Confluent monolayers were washed with 200 ul 
of a buffer containing 10 mM HEPES, 0.15 M NaCl, 4 mM KC1, and 
11 mM glucose, pH 7.45 (buffer A) supplemented with 1 M NaCl, and 
then washed with 200 ul of buffer A. Triplicate wells were incubated 
at 4°C with various concentrations of either h-rTFPI or h-rTFPI-C in 
a volume of 100 ul of 10 mM HEPES, 0.15 M NaCl, 4 mM KC1, and 
11 mM glucose, pH 7.45, supplemented with 5 mM CaCl2 (buffer B) 
containing 1 mg/ml BSA. The incubation was performed at 4°C to 
prevent endocytosis of bound h-rTFPI. After 2 h, the incubating 
mixtures were removed, and the cells were washed twice in ice-cold 
buffer B not containing BSA as quickly as possible. After washing, the 
cells were scraped with 200 JJ.1 of 0.5% Triton X-100 in phosphate-
buffered saline containing 50 mM benzamidine and 10 mM EDTA, 
and then incubated for 10 min with 100 ul of 25 mM NH4OH to 
remove cytoskeletal elements, according to the methods outlined in 
Knudsen et al.[20]. The amounts of h-rTFPI in the Triton X-100 and 
NH4OH aliquots were quantified by sandwich ELISA. In the current 
study, the total amount of h-rTFPI in Triton X-100 and NH4OH was 
defined as the amount of TFPI bound to hSMCs. 
2.4. Measurement of h-rTFPI antigen by a sandwich ELISA 
h-rTFPI antigen was measured by a sandwich ELISA using mono-
clonal (HTFPIK-9) and polyclonal antibodies as described in a pre-
vious paper[19]. To evaluate the effect on the ELISA of components 
in the cell lysate other than TFPI, we performed the recovery studies 
with spiked samples which were prepared by adding various concen-
trations of h-rTFPI to the cell lysate. As a result, it was observed that 
no components had any effect on the ELISA (data not shown). 
2.5. Statistics 
Statistical analysis was performed by means of the unpaired Stu-
dent's Mest. In this test, data are considered significant if P < 0.05. 
3. Results 
3.1. Effect of h-rTFPI on the proliferation of neonatal hSMCs 
We investigated the effect of varying concentrations of h-
rTFPI on the proliferation of the cultured neonatal hSMCs. 
The neonatal hSMCs did not show a hill and valley growth 
pattern, but grew in sheets. As shown in Fig. 1, h-rTFPI 
inhibited the proliferation of the hSMCs in a dose-dependent 
manner and that its inhibition was very dramatic at day 8. No 
change of morphological feature was observed in the hSMCs 
in the presence of h-rTFPI. To identify the functional domain 
in h-rTFPI, we compared the inhibitory activity of h-rTFPI 
with that of h-rTFPI-C which lacks the amino acid sequence 
of Gly250-Met276 in the C-terminal region. As shown in Fig. 2, 
it was clear that hSMC proliferation was not inhibited by h-
rTFPI-C. In fact, h-rTFPI-C weakly enhanced the prolifera-
o 
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Fig. 1. Effect of h-rTFPI on cultured neonatal hSMC proliferation. 
hSMCs were plated sparsely (104 cells/well) and at 24 h the culture 
medium was changed to a fresh growth medium containing various 
concentrations of h-rTFPI. After that, we changed the fresh medium 
every 2 days. For growth rate determination, cells were detached 
from 4 wells and counted in a Coulter counter. Each point indicates 
the mean cell number ±SD (n = 4). The data for each culture day 
represents a significant difference from the data for no h-rTFPI 
when compared by means of the unpaired Student's Mest if 
*P<0.05 or **P<0.01. (o) no h-rTFPI; (■) 47 nM h-rTFPI; ( A ) 
236 nM h-rTFPI; (•) 1179 nM h-rTFPI. 
tion of hSMCs. No cytotoxicity due to h-rTFPI was detected 
(data not shown). 
3.2. Effects of heparin on the binding of h-rTFPI and 
h-rTFPI-C to hSMCs 
To examine the interaction of h-rTFPI with hSMCs, we 
performed binding studies. As shown in Fig. 3, h-rTFPI 
(300 nM in buffer B) bound to hSMCs with a mean binding 
of 1135 ± 229 fmol/well. In the case of h-rTFPI-C, the binding 
was reduced by about 50% (mean binding: 533 ±56 fmol/ 
well). It was previously reported that one of the heparin bind-
ing sites in TFPI exists in the C-terminal region [17,21] and 
that the binding of h-rTFPI to the cultured ovarian carcinoma 
cells in the absence of factors Vila and Xa is dramatically 
inhibited by an addition of heparin [22]. Therefore, we exam-
ined the effect of heparin on the binding of h-rTFPI and h-
rTFPI-C, respectively, to hSMCs. The addition of heparin to 
h-rTFPI diminished the binding of h-rTFPI to hSMCs in a 
dose-dependent manner (Fig. 3), and the binding of h-rTFPI 
in the presence of high concentrations of heparin approached 
that of h-rTFPI-C, while the binding of h-rTFPI-C was not 
reduced at all. On the basis of these results, it was supposed 
that the abrogation of the binding of h-rTFPI caused by the 
addition of heparin (heparin-inhibitable binding) was mainly 
responsible for the anti-proliferative effect of h-rTFPI against 
hSMCs. To determine the binding constant for the heparin-
inhibitable binding of h-rTFPI to hSMCs, hSMCs were incu-
bated with increasing concentrations of h-rTFPI, and then the 
amount of heparin-inhibitable binding was determined by 
subtracting h-rTFPI's binding in the presence of heparin (60 
ug/ml) from that in the absence of heparin. The representative 
binding isotherms in five experiments are shown in Fig. 4, 
with a Scatchard plot in the inset. The binding was saturable 
at about 500 nM, and the Scatchard analysis showed a single 
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Fig. 2. Effect of h-rTFPI-C on cultured neonatal hSMC prolifera-
tion. hSMCs were cultured in a growth medium containing various 
concentrations of h-rTFPI-C as described in the legends for Fig. 1. 
Results are expressed as the mean cell number ±SD (n = 4) at day 
8. **P < 0.01 versus no h-rTFPI-C. 
class of binding sites. In addition, from a mean of five experi-
ments, we determined a mean value of K& with 526 ±189 nM 
and the number of the binding sites with 5.87 (±3.69)X 107 
sites/cell. 
3.3. Identification of the h-rTFPI sites involved in h-rTFPI's 
binding to hSMCs 
In order to identify the h-rTFPI sites involved in h-rTFPFs 
binding to hSMCs, we performed a competitive binding assay 
1 10 
Heparin ( ug/ml ) 
Fig. 3. Effect of heparin on the binding of h-rTFPI and h-rTFPI-C 
to hSMCs. hSMCs were incubated with either h-rTFPI or h-rTFPI-
C in the presence of increasing concentrations of heparin at 4°C. 
After incubation for 2 h, hSMCs were washed, and the bound 
TFPI was determined by the ELISA as described under Section 2. 
Results are expressed as the mean amount of TFPI bound ± SD 
(fmol/well) (n = 3): (•) 257 nM h-rTFPI; (■) 320 nM h-rTFPI-C. 
using TFPI-related peptides. As shown in Fig. 5, the addition 
of the CTP23 peptide (Lys254-Met276) to h-rTFPI abolished h-
rTFPI's binding in a dose-dependent manner. To further in-
vestigate the role of the basic amino acid cluster region in-
volved in the CTP23 peptide, CTP11 (Lys254-Val264) and 
CTP12 (Lys265-Met276) peptides were used in a competitive 
assay. Fig. 5 shows that the CTP11 peptide drastically inhib-
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Fig. 4. Determination of the kinetic constant for the heparin-inhibitable binding of h-rTFPI to hSMCs. The heparin-inhibitable binding was de-
termined by subtracting the h-rTFPI bound in the presence of heparin (60 ug/ml) from that bound in the absence of heparin. Inset: Scatchard 
plot for heparin-inhibitable binding of h-rTFPI to hSMCs. 
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Fig. 5. Effect of the TFPI-derived C-terminal peptides on binding of h-rTFPI to hSMCs. After 300 nM h-rTFPI was incubated with hSMCs in 
the presence of some peptides or heparin (60 |ig/ml) for 2 h at 4°C, the bound TFPI was determined by the ELISA. In the experiments, we 
used the CTP23 peptide (Lys254-Met276) (0.7-69 uM), 138 uM CTPll peptide (Lys254-Val264), and 135 uM CTP12 peptide (Lys265-Met276) as 
the C-terminal peptide. Columns and error bars represent the mean and SD of triplicate samples, respectively. T<0.05 and **P<0.01 versus 
the control groups which contain h-rTFPI only. 
ited h-rTFPI's binding, while the CTP12 peptide did not. On 
the basis of these results, it seems likely that the basic amino 
acid cluster region in TFPI plays a significant role in h-
rTFPI's binding to hSMCs. 
4. Discussion 
Many biological processes of SMCs are very important in 
the development of atherosclerosis and restenosis following 
angioplasty [1,2], and the hypercoagulation triggered by TF 
in arterial lesions is one such significant process [12]. Jang et 
al. [8] recently found that TFPI treatment in a rabbit athero-
sclerotic model reduced restenosis and suggested that TFPI 
contributes to the inhibition of the TF-mediated extrinsic co-
agulation pathway. Sato et al. also reported that TF induces 
the migration of cultured aortic SMCs in concert with factor 
Vila and that its induction is completely prevented by an 
addition of h-rTFPI [23]. However, the direct effect of h-
rTFPI on the proliferation of SMCs has not yet been re-
ported. Therefore, in the present study, we investigated the 
effect of h-rTFPI on the proliferation of cultured hSMCs. 
We found that h-rTFPI inhibits neonatal hSMC proliferation 
in growth medium, while h-rTFPI-C does not. Experiments 
on the binding of h-rTFPI to hSMCs suggested that the anti-
proliferative effect of h-rTFPI is mediated by the binding of 
its C-terminal region with hSMCs. As expected, a very weak 
anti-proliferative effect of h-rTFPI on the hSMCs taken from 
media of adult arteries and on human fibroblasts was ob-
served (data not shown). Therefore, it appears that the anti-
proliferative effect of h-rTFPI is specific to the cultured 
hSMCs with high proliferative potential and that the C-termi-
nal basic region in h-rTFPI contributes to this effect. The 
cultured neonatal hSMCs have some characteristics similar 
to the 'synthetic' hSMCs in the restenosed lesions [14]. On 
the basis of these results, we think that h-rTFPI is a strong 
candidate to prevent restenosis following tissue injury through 
its anti-proliferative function against SMCs. 
In the present study, we could not locate a precise mecha-
nism for the anti-proliferative function mediated via the C-
terminal region in h-rTFPI nor could we identify the specific 
binding substances or receptors on the surface of hSMCs. 
Novotny et al. previously reported that TFPI covalently binds 
to apolipoprotein A-II [24]. And also, apolipoprotein A-II 
reduces EGF-induced DNA synthesis in SMCs [25]. There-
fore, it is possible that the anti-proliferative effects of h-rTFPI 
may be mediated through the interaction between h-rTFPI 
and apolipoprotein A-II, although the precise mechanism still 
remains unknown. It is well known that the C-terminal basic 
region of TFPI is a main heparin-binding region [17,21]. 
Among the heparin binding proteins, the significance of the 
anti-proliferative effect of platelet factor-4 (PF-4) [26] and 
histidine-rich glycoprotein (HRG) [27] have been well eval-
uated using endothelial cells and fibroblasts, respectively. 
The effect is thought to be mainly attributable to the compe-
tition with the heparin-binding growth factors such as FGFs 
for cell surface glycosaminoglycans (GAG), because both PF-
4 [28] and HRG [27] can bind to the GAGs on the surface of 
cultured cells. In addition, it was recently reported that h-
rTFPI could bind to heparan sulfate on ryudocan prepared 
from endothelium-like cells with a high affinity [29]. There-
fore, it seems likely that h-rTFPI can prevent the proliferation 
of hSMCs by binding to GAGs. 
Low-density lipoprotein receptor-related protein (LRP) has 
been reported to be a receptor of TFPI on cell surfaces [30]. 
However, it is unlikely that LRP is involved in the interaction 
of h-TFPI with hSMCs, because the affinity of h-rTFPI for 
120 
L R P is much higher than that in our present study, as com-
pared with the KA value (30 n M versus 526 nM) [30]. In 
addition to this receptor, it has been recently demonstrated 
that TFPI synthesized by endothelial cells localizes in caveolae 
and that its localization is mediated by glycosyl phosphatidyl-
inositol (GPI) [31]. Therefore, GPI is considered to be a pos-
sible receptor for h- rTFPI binding. 
In conclusion, h - rTFPI exhibits inhibitory activity toward 
the growth of hSMCs in addition to its anticoagulant activity. 
Therefore, h- rTFPI may be a promising medicine for prevent-
ing restenosis postangioplasty. 
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